DUBLIN, Sept. 12, 2017 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
was named to Fortune magazine's list of fastest growing companies
for 2017. In Fortune's annual rankings, Jazz was named the
78th fastest growing company.
"We are honored to be recognized with some of the most
innovative companies in the world," said Bruce Cozadd,
chairman and chief executive officer of Jazz Pharmaceuticals.
"Our continued growth is a testament to our hard-working, talented
employees who are dedicated to bringing innovative therapies to
market for life-threatening or complex conditions that have few if
any treatment options."
Fortune magazine's 100 fastest-growing companies are publicly
traded companies ranked by revenue growth rate, EPS growth rate and
three-year annualized total return for the period ended
June 30, 2017. The overall rank is
based on the sum of these three ranks.
Jazz – which was recognized by Fortune as the fastest growing
company in 2013 – is a rapidly growing international
biopharmaceutical company that is investing in optimizing the
growth of its key products and advancing and expanding its R&D
pipeline with a goal of bringing new therapeutic options to
patients.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international
biopharmaceutical company focused on improving patients' lives by
identifying, developing and commercializing meaningful products
that address unmet medical needs. The company has a diverse
portfolio of products and product candidates with a focus in the
areas of sleep and hematology/oncology. In these areas, Jazz
Pharmaceuticals markets Xyrem® (sodium oxybate) oral
solution, Erwinaze® (asparaginase Erwinia
chrysanthemi), Defitelio® (defibrotide sodium) and
Vyxeos™ (daunorubicin and cytarabine) liposome for injection in the
U.S. and markets Erwinaze® and Defitelio®
(defibrotide) in countries outside the U.S. For more information,
please visit www.jazzpharmaceuticals.com.
"Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements,
including, but not limited to, statements related to Jazz
Pharmaceuticals' investing in optimizing the growth of its key
products and advancing and expanding its R&D pipeline with a
goal of bringing new therapeutic options to patients, and other
statements that are not historical facts. These
forward-looking statements are based on the company's current
plans, objectives, estimates, expectations and intentions and
inherently involve significant risks and uncertainties.
Actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without
limitation, risks and uncertainties associated with: effectively
commercializing the company's products and product candidates; the
regulatory approval process; pharmaceutical product development and
the uncertainty of clinical success; and the ability to achieve
expected future financial performance and results; and other risks
and uncertainties affecting the company, including those described
from time to time under the caption "Risk Factors" and elsewhere in
Jazz Pharmaceuticals plc's Securities and Exchange Commission
filings and reports (Commission File No. 001-33500), including the
company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2017 and future filings and
reports by the company, including the company's Quarterly Report on
Form 10-Q for the quarter ended June
30, 2017. Other risks and uncertainties of which the
company is not currently aware may also affect the company's
forward-looking statements and may cause actual results and timing
of events to differ materially from those anticipated. The
forward-looking statements herein are made only as of the date
hereof or as of the dates indicated in the forward-looking
statements, even if they are subsequently made available by the
company on its website or otherwise. The company undertakes
no obligation to update or supplement any forward-looking
statements to reflect actual results, new information, future
events, changes in its expectations or other circumstances that
exist after the date as of which the forward-looking statements
were made.
Logo -
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg